Clinical Trial Update: EXOMIND (BTL-995) for Reduction of Binge-eating [NA]

View source ↗

Summary

Clinical trial update indicating a completed study evaluating EXOMIND (BTL-995) for reducing binge eating in individuals with Binge Eating Disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Binge Eating Disorder

Drugs mentioned

• EXOMIND (BTL-995)

Snippet

Sponsor: BTL Industries Ltd. | Conditions: Binge-Eating Disorder | NA | Status: COMPLETED